Jointown Pharmaceutical Group Co (SHSE:600998) Net Income From Continuing Operations : ¥2,233 Mil (TTM As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Jointown Pharmaceutical Group Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Jointown Pharmaceutical Group Co's net income from continuing operations for the three months ended in Mar. 2024 was ¥542 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ¥2,233 Mil.

Jointown Pharmaceutical Group Co Net Income From Continuing Operations Historical Data

The historical data trend for Jointown Pharmaceutical Group Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jointown Pharmaceutical Group Co Net Income From Continuing Operations Chart

Jointown Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

1,781.48

3,385.08

2,608.38

2,285.53

2,289.66

Jointown Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															598.44	816.39	462.47	412.37	542.17

Jointown Pharmaceutical Group Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,233 Mil.

Jointown Pharmaceutical Group Co (SHSE:600998) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Jointown Pharmaceutical Group Co Ltd (SHSE:600998) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

No 8 Longyang Road, Hanyang District, Wuhan, CHN, 430051

Website

http://www.jztey.com

Jointown Pharmaceutical Group Co Ltd is engaged in the business of wholesaling drugs and medical devices. The company offers logistics and other value-added services and primarily serves medical institutions, wholesale enterprises, and retail pharmacies.

Executives

Liu Yi Chang	Director
Ai Hua	Director
Wang Qi Bing	senior management
Gong Yi Hua	Directors, senior managers
Lin Xin Yang	Directors, senior managers
Yang Ju Mei	senior management
Chen Qi Ming	Directors, senior managers
Chen Li	Supervisors
Guo Lei	senior management
Liu Su Fang	senior management
Xu Ming Zhen	senior management
Chen Song Bai	senior management
Huang Li Hua	senior management
Wang Jia Ming	senior management
Chen Bo	senior management

Jointown Pharmaceutical Group Co (SHSE:600998) Headlines

No Headlines